Celldex reports Q3 2026 results, confirms 2027 BLA plan for barzolvolimab in CSU
Celldex says Phase 3 CSU trials met all endpoints and the enrolling cold urticaria study continues, with cash of $650.3 million seen funding operations into 2028.
SEC filing